Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

ConferenceTransCon® PTHPositive

AI Analysis

Summary

Ascendis Pharma announced it will present combined skeletal data from Phase 2 PaTH Forward and Phase 3 PaTHway trials of TransCon® PTH at ASBMR 2026, showing normalization of bone mass and microarchitecture over 5 years in hypoparathyroidism patients.

Clinical Trial Data

Phase

Phase 2/Phase 3

Importance:5/10

Sentiment:

0.60

ASBMR 2026HypoparathyroidismAchondroplasiaTransCon PTHBone healthClinical data presentation

Related Companies

$ASND

Read the original article

Published by GlobeNewswire Pharma on October 6, 2026 1:15 PM

Read Original